Amit Kumar, Chief Executive Officer at Anixa Biosciences Inc (ANIX), bought 5,000 shares at $2.76 ($14K) on 2026-09-10, disclosed to the SEC on 2026-09-11.
CEO Amit Kumar purchased 5,000 shares at $2.76 on September 10, signaling confidence in the stock's value following a sharp recent decline. This insider buying comes as the company secures new intellectual property and maintains a lean cash burn profile.
The stock has dropped 10.89% over the last 5 days and 15.3% over the last 30 days, trading at $2.74, which is 49.79% below its 52-week high of $5.46.
1) The company views 2026 as a 'pivotal year' for advancing a breast cancer vaccine and CAR-T therapy (Feb 10, 2026). 2) Anixa secured a Korean patent for its breast cancer vaccine on June 30, 2026. 3) The stock was upgraded to a Zacks Rank #1 (Strong Buy) on July 22, 2026.
The stock is currently trading at a forward P/E of -8.87, indicating the company is unprofitable, and short interest represents 3.03% of the float.
Nothing distinguishes this filing.
| Filing → |
| ANIX | BUY | 2026-08-03 | $17K | — | Filing → |
| ANIX | BUY | 2026-07-28 | $17K | — | Filing → |
| ANIX | BUY | 2026-07-27 | $11K | — | Filing → |